GlassScriptPhysician profile
Barry J Leader
NPI 1952341554
$5,275.93
in general payments reported to CMS, 2019-2025
22 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,499 · 2020: $142 · 2021: $711 · 2022: $268 · 2023: $303 · 2024: $116 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,890.79 | 2019 | |
| Allergan, INC. | $575.29 | 2019-2022 | |
| Alcon Vision LLC | $324.75 | 2019-2025 | Clareon, Rocklatan, Eysuvis |
| Johnson & Johnson Surgical Vision, INC. | $232.86 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $196.36 | 2021 | |
| Bausch & Lomb Americas INC. | $178.07 | 2023-2025 | Vyzulta, Xiidra, Miebo |
| Aerie Pharmaceuticals, INC. | $146.51 | 2019-2021 | |
| Oyster Point Pharma, INC. | $144.35 | 2022-2025 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $124.99 | 2021 | |
| Abbvie INC. | $97.65 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $61.20 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $44.53 | 2019 | |
| Shire North American Group INC | $43.66 | 2019 | |
| Kala Pharmaceuticals, INC. | $30.08 | 2019 | |
| Akorn, INC. | $29.41 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $28.43 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $25.97 | 2020 | |
| Novartis Pharmaceuticals Corporation | $23.30 | 2019 | |
| Dompe US, INC. | $23.11 | 2024 | Oxervate |
| Harrow Eye, LLC | $22.81 | 2024 | Vevye |
| Ivantis, INC | $17.41 | 2020 | |
| Mallinckrodt Hospital Products INC. | $14.40 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Leader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.